Metformin, rosiglitazone, or both for obese women with polycystic ovary syndrome?
In this issue, Yujing et al. (1) compared the effects of the two most commonly used insulin sensitizers for obese, insulin resistant women with polycystic ovary syndrome (PCOS; by Rotterdam criteria). Two hundred four participants were randomized into three comparable groups. Group 1 received 1,500 mg metformin, group 2 r eceived 4 mg of rosiglitazone, and group 3 received 1000 mg metformin plus 4 mg rosiglitazone for six months. In addition to drugs, dietary adjustment and moderate-strength physical exercises for 40 minutes three times a week were recommended to all groups.
Source: Fertility and Sterility - Category: Reproduction Medicine Authors: Sushila Arya, Karl R. Hansen, Robert A. Wild Tags: Reflections Source Type: research
More News: Avandia | Diets | Eating Disorders & Weight Management | Fortamet | Insulin | Metformin | Nutrition | Obesity | Ovaries | Polycystic Ovary Syndrome | Reproduction Medicine | Women